Clinical Trials Sponsored by Hana Borrer

Total 2232 results

Dana-Farber Cancer Institute

Recruiting

Geriatric Thoracic Surgery Ambulation Challenge

Surgery | Thoracic Diseases | Therapy, Exercise

United States
Dana-Farber Cancer Institute

Recruiting

Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma

Head and Neck Cancer

United States
Dana-Farber Cancer Institute

Recruiting

Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies

Lymphoproliferative Disorders | Non-Hodgkin's Lymphoma | Hodgkin's Disease | Leukemia, Lymphocytic, Chronic

United States
Dana-Farber Cancer Institute

Completed

Prospective Study of BK Virus Disease After Allogeneic Hematopoietic-cell Transplantation: Defining BK Disease's Natural History, Clinical Spectrum, Immunology, and Outcomes

BK Virus Infection

United States
Dana-Farber Cancer Institute

Active, not recruiting

A Pilot Study of Quantitative Tumor Oxygen Measurements in Cervical Cancer

Cervical Cancer | Gynecologic Cancer

United States
Dana-Farber Cancer Institute

Active, not recruiting

The SPOT-HPV Study

HPV Infection | HPV Positive Oropharyngeal Squamous Cell Carcinoma

United States
Dana-Farber Cancer Institute

Active, not recruiting

Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck

Recurrent Head and Neck Carcinoma | Head and Neck Cancer Metastatic | Head or Neck Cancer

United States
Dana-Farber Cancer Institute

Active, not recruiting

Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma

Follicular Lymphoma

United States
Dana-Farber Cancer Institute

Active, not recruiting

Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa

Breast Cancer

United States
Dana-Farber Cancer Institute

Completed

OPTimizing Treatment Focused Genetic Testing IN Cancer (OPT-IN)

Breast Cancer | Pancreatic Cancer | Ovarian Cancer | Prostate Cancer

United States
Dana-Farber Cancer Institute

Active, not recruiting

The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study

Pediatric Solid Tumor

United States
Dana-Farber Cancer Institute

Active, not recruiting

T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)

Breast Cancer

United States
Dana-Farber Cancer Institute

Suspended

Stereotactic Magnetic Resonance Guided Radiation Therapy

Lung Cancer | Prostate Cancer | Mesothelioma | Liver Metastases | Pancreas Cancer | Renal Cancer | Brain Metastases | Spine Metastases | Borderline Resectable Pancreatic Carcinoma | Adrenal Metastases | Oligoprogressive Nodal Metastases | Metachronous Nodal Metastases | Synchronous Nodal Metastases

United States
Dana-Farber Cancer Institute

Active, not recruiting

Stereotactic Radiation in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases

Small Cell Lung Cancer | Brain Metastases

United States
Dana-Farber Cancer Institute

Active, not recruiting

Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone

Bone Cancer

United States
Dana-Farber Cancer Institute

Completed

Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors

Carcinoid Tumor

United States
Dana-Farber Cancer Institute

Active, not recruiting

Post-treatment Surveillance in HPV+ Oropharyngeal SCC

Oropharyngeal Squamous Cell Carcinoma | HPV

United States
Dana-Farber Cancer Institute

Active, not recruiting

Screening With Whole Body MRI For Detection Of Primary Tumors In Children And Adults With Li-Fraumeni Syndrome (LFS) And Other Cancer Predisposition Syndromes

Li-Fraumeni Syndrome

United States
Dana-Farber Cancer Institute

Completed

A Phase II, Prospective Study of MRI in the Reclassification of Men Considering Active Surveillance in Prostate Cancer

Prostate Cancer

United States
Dana-Farber Cancer Institute

Completed

Cabozantinib With Topotecan-Cyclophosphamide

Refractory Ewing Sarcoma | Refractory Osteosarcoma | Relapsed Ewing Sarcoma | Relapsed Osteosarcoma

United States
Dana-Farber Cancer Institute

Completed

A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency

Advanced Cancers

United States
Dana-Farber Cancer Institute

Terminated

Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies

Hematologic Malignancy

United States
Dana-Farber Cancer Institute

Completed

Study of Vitamin D in Untreated Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

United States
PATH
Ghana Health Services

Completed

Ghana: The Barriers and Facilitators of Scaling up the Ellavi UBT for Postpartum Hemorrhage

Postpartum Hemorrhage

Ghana
Dana-Farber Cancer Institute

Completed

Clinician Decision Support Algorithm for Chemotherapy-Induced Peripheral Neuropathy

Cancer | Chemotherapy-induced Peripheral Neuropathy

United States
Dana-Farber Cancer Institute

Withdrawn

Abemaciclib + Pembrolizumab In Glioblastoma

Glioblastoma

United States
Dana-Farber Cancer Institute

Completed

XL-184+Abiraterone in Post-Chemo CRPC

Prostate Cancer

United States
Dana-Farber Cancer Institute

Terminated

Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors

Sarcoma | Soft Tissue Sarcoma | Clear Cell Renal Cell Carcinoma | Osteosarcoma | Sarcoma, Ewing | Ewing Sarcoma | Rhabdoid Tumor | Renal Tumor | Rhabdomyosarcoma | Wilms Tumor | Non-Rhabdomyosarcoma Soft Tissue Sarcoma, Nos

United States
Hani Alhadad

Completed

Endoscopic Versus Percutaneous Biliary Drainage for Resectable Pancreatic Head Cancer

Obstructive Jaundice | Pancreatic Head Cancer

Egypt
Dana-Farber Cancer Institute

Completed

Whole-Exome Sequencing (WES) of Cancer Patients

Lung Adenocarcinoma | Colon Adenocarcinoma

United States
Dana-Farber Cancer Institute

Completed

Smart Phone App Intervention In Young Adults With Cancer

Cancer | Young Adults | Smartphone Application | Behavioral Intervention

United States
Dana-Farber Cancer Institute

Withdrawn

Ferumoxytol-Enhanced MRI in Adult/Pedi Sarcomas

Soft Tissue Sarcoma

United States
Dana-Farber Cancer Institute

Completed

FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer

Gastric Cancer | Esophageal Cancer

United States
Dana-Farber Cancer Institute

Completed

Personal Web Page In Clinical Trial Participant Education

Kidney Cancer | Prostate Cancer | Genitourinary Cancer

United States
Dana-Farber Cancer Institute

Completed

Comparison of Creatinine Clearance Calculation for Estimation of GFR in Patients Receiving HD Methotrexate

CNS Lymphoma | CNS Involvement of Systemic Lymphoma

United States
Dana-Farber Cancer Institute

Terminated

Harnessing the Effect of an Open-Label Placebo on Fatigue in Cancer Survivors

Fatigue in Cancer Survivors

United States
Dana-Farber Cancer Institute

Completed

A Nurse Led Project to Introduce Hand Lettering as a Form of Creative Art Expression to Patients in an Ambulatory Oncology Setting

Anxiety

United States
Nasser Hanna

Completed

Understanding the Molecular and Genetic Differences Between Germ Cell Tumor at the Time of the Initial Diagnosis and at Late Relapse

Neoplasms, Germ Cell and Embryonal

United States
Dana-Farber Cancer Institute

Completed

Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma

Glioblastoma

United States
Dana-Farber Cancer Institute

Completed

Procurement of Follicular B Cell Lymphoma Cells for the Purpose of Possible Use in Future Clinical Trials

Non-Hodgkin's Lymphoma

United States
Dana-Farber Cancer Institute

Completed

Feasibility Study of Low Level Light Therapy for Prevention of Oropharyngeal Mucositis in Pediatric Transplants Patients

Low Level Light Therapy | Oropharyngeal Mucositis | Myeloablative Hematopoietic Cell Transplantation

United States
Dana-Farber Cancer Institute

Terminated

Breast MRI for Newly Diagnosed Breast Cancer:Impact on Re-excision Lumpectomy

Breast Cancer

United States
Dana-Farber Cancer Institute

Completed

Healthy Living After Cancer: Weight Management Pilot Study

Weight Loss Program After Cancer Diagnosis

United States
Dana-Farber Cancer Institute

Withdrawn

Stereotactic Boost for Oropharyngeal Squamous Cell Carcinoma

Squamous Cell Carcinoma of the Oropharynx

United States
Dana-Farber Cancer Institute

Withdrawn

Clofarabine for Langerhans in Pedi

Langerhans Cell Histiocytosis
Dana-Farber Cancer Institute

Completed

Melatonin Versus Placebo in Breast Cancer

Breast Cancer

United States
Dana-Farber Cancer Institute

Completed

iCAT for Recurrent/Refractory/HR Solid Tumors

Sarcoma | Neuroblastoma | Wilms Tumor | Pediatric Solid Tumor

United States
Dana-Farber Cancer Institute

Terminated

Dasatinib in Advanced Squamous Cell Lung Cancer

Squamous Cell Lung Cancer

United States
Dana-Farber Cancer Institute

Completed

SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT)

Multiple Myeloma | Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma

United States
Dana-Farber Cancer Institute

Completed

Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma

Melanoma (Skin)

United States

Clinical Trials Sponsored by Hana Borrer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations